DOCSLIB.ORG

Society of Actuaries Research Brief Impact of COVID-19, May 15, 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Society of Actuaries Research Brief Impact of COVID-19, May 15, 2020 Society of Actuaries Research Brief Impact of COVID-19 May 15, 2020 May 2020 2 Society of Actuaries Research Brief Impact of COVID-19 May 15, 2020 AUTHORS R. Dale Hall, FSA, MAAA, CERA, CFA Cynthia S. MacDonald, FSA, MAAA Peter J. Miller, ASA, MAAA Achilles N. Natsis, FSA, MAAA Lisa A. Schilling, FSA, EA, FCA, MAAA Steven C. Siegel, ASA, MAAA J. Patrick Wiese, ASA REVIEWERS Michael C. Dubin, FSA, FCAS, FCA, MAAA Timothy J. Geddes, FSA, EA, FCA, MAAA Daniel J. Geiger, PhD Umesh Haran, FSA, ACIA, CERA Jing Lang, FSA, FCIA Ronald Poon Affat, FSA, FIA, MAAA, CFA Max J. Rudolph, FSA, MAAA, CERA, CFA Nazir Valani, FSA, FCIA, MAAA Greger Vigen Caveat and Disclaimer This study is published by the Society of Actuaries (SOA) and contains information from a variety of sources. The study is for informational purposes only and should not be construed as professional or financial advice. The SOA does not recommend or endorse any use of the information provided in this study. The SOA makes no warranty, express or implied, or representation whatsoever and assumes no liability in connection with the use or misuse of this study. Copyright © 2020 by the Society of Actuaries. All rights reserved. Copyright © 2020 Society of Actuaries 3 CONTENTS Introduction.............................................................................................................................................................. 5 Key Statistics............................................................................................................................................................. 6 Reported Cases .............................................................................................................................................................. 6 Worldwide Cases ............................................................................................................................................... 6 U.S. and Canadian cases .................................................................................................................................... 7 Case Fatality Rates ......................................................................................................................................................... 9 CFRs by Age Group ............................................................................................................................................ 9 U.S. Subpopulations ........................................................................................................................................ 11 CFR Limitations ................................................................................................................................................ 12 Reported Cases vs. Actual Cases..................................................................................................................... 15 COVID-19 Mortality Rate Curves ................................................................................................................................. 15 COVID-19 Mortality Relative to All Causes of Death .................................................................................................. 18 Excess Mortality ........................................................................................................................................................... 18 Comparison to Past Pandemics and Influenza ........................................................................................................... 19 COVID-19 and Past Epidemics and Pandemics .............................................................................................. 19 COVID-19 and Influenza .................................................................................................................................. 20 Health Care Cost and Utilization ................................................................................................................................. 22 Supply of Medical Resources .......................................................................................................................... 23 Hospitalization Rates ....................................................................................................................................... 23 Comorbidities .................................................................................................................................................. 28 COVID-19 Treatment ....................................................................................................................................... 30 Non-COVID-19 Health care ............................................................................................................................. 32 Mental Health .................................................................................................................................................. 32 Infection Spread Rate .................................................................................................................................................. 33 Economic and Asset Impact .................................................................................................................................... 35 Macroeconomic Variables ........................................................................................................................................... 35 Monetary and Fiscal Policy ............................................................................................................................. 35 Employment..................................................................................................................................................... 37 Gross Domestic Product .................................................................................................................................. 39 Asset Values and Volatility........................................................................................................................................... 40 Low Interest Rate Environment .................................................................................................................................. 41 Reinvestment and Default Risk ................................................................................................................................... 42 Impact on Insurance Industry .................................................................................................................................. 44 Impact on Life Insurance Companies .......................................................................................................................... 44 Impact on Health Insurance Companies ..................................................................................................................... 46 Impact on Property/Casualty Coverages .................................................................................................................... 48 Business Interruption Insurance ..................................................................................................................... 49 Cancellation Insurance .................................................................................................................................... 49 Workers’ compensation .................................................................................................................................. 49 Personal Automobile Insurance ...................................................................................................................... 50 Medical Malpractice Insurance ...................................................................................................................... 51 Financial Guaranty/Mortgage Guaranty ........................................................................................................ 51 Impact on Captive Insurance Companies ................................................................................................................... 51 Changes in Insurance Regulation and Contractual Requirements ............................................................................ 51 Cyber Risk ..................................................................................................................................................................... 52 Impact on Retirement Plans .................................................................................................................................... 52 Corporate Defined Benefit Retirement Plans ............................................................................................................. 53 Copyright © 2020 Society of Actuaries 4 Multiemployer Defined Benefit Retirement Plans ..................................................................................................... 54 Public Defined Benefit Retirement Plans .................................................................................................................... 55 Defined Contribution Retirement Plans ..................................................................................................................... 56 Impact on Social Insurance ..................................................................................................................................... 56 U.S. Social Insurance PRograms .................................................................................................................................
Load more

Recommended publications
  • Actuaries Abroad
    Actuaries Abroad California Actuarial Student Summit 2019 UC Santa Barbara Andrew Peterson, FSA, EA, MAAA Senior Director, International, SOA May 25, 2019 Discussion topics ▪ Global actuarial profession ▪ Becoming an actuary & SOA pathway ▪ Working internationally: qualifications & job market 2 Around the Globe – Snapshot Global Actuarial Profession (Total ~80,000) 2% 0% 3% 4% North America 8% Europe Asia 44% Oceania Latin America Africa 38% Middle East Estimated results based on 2018 Intl. Actuarial Association (IAA) data; distributions are approximate due to potential overlap in membership in different regions. 3 Around the Globe – Snapshot SOA Global Footprint (2018) SOA Members + Candidates in Asia (2018) 2% 1% 1% 1,261 22 China 4% Hong Kong 4% 1,221 3,048 United States Malaysia 5% 30% Canada Korea, Republic of China Taiwan 11% 5,213 Asia-Pacific Thailand 20,560 Singapore Latin America 11% Philippines Rest of the World 20% Vietnam 11% Japan Members : 31,325 Indonesia CAS Global Footprint (2018) IFoA Global Footprint (2017/18) 135 186 79 105 UK 538 4,765 US 903 India 559 Canada Ireland 1185 Bermuda South Africa 1636 China/HK/Singapore China 16253 6,944 UK/Switzerland ROW ROW 6064 Members : 8,352 Includes both Actuaries (~15,000) + Students (~16,000) = ~31,000 4 Becoming an actuary & SOA pathway Becoming an Actuary – 4 Primary Intl. Credentials SOA (US)—ASA, FSA • Practice Areas: All covered • Choose specialty track after obtaining ASA • Self-study or university curriculum to master actuarial concepts • Advance through series of exams to earn credential • Complete/attend certain modules/courses https://www.soa.org/education/general-info/default/ CAS (USA)– ACAS, FCAS • Practice Area: Property & Casualty • Self-study or university curriculum to master concepts • University and exam pathways • Advance through a series of exams to earn credential • Complete/attend certain modules/courses https://www.casact.org/admissions/process/ 6 Becoming an Actuary – 4 Primary Intl.
    [Show full text]
  • Exam FM: Financial Mathematics
    Welcome! The Actuarial Science program prepares student for careers as actuaries. It helps them learn material that is included in processional examinations administered by the Society of Actuaries and Casualty Actuary Society, which actuarial students must pass in order to achieve professional status. Thank you for your interest in our Actuarial Science Program at the University of Iowa. The Actuarial Science program prepares students for careers as actuaries. It helps them learn material that is included in professional examinations administered by the Society of Actuaries, which actuarial students must pass in order to achieve professional status. In addition to actuarial science courses, students can take courses in preparation for business aspects of the actuarial profession such as accounting, law, finance, insurance, and economics. The Society of Actuaries (SOA) has recognized University of Iowa’s actuarial science program as a Center of Actuarial Excellence (CAE). There are eight criteria for the designation, including curriculum, faculty composition, graduate quality, connection to industry, and research/scholarship. We are a small department in a large University and graduate between 20-15 students each year. We do have SELECTIVE admission due to the difficulty of the professional examinations. Students interested in becoming actuaries should declare an Interest in Actuarial Science as their major when they ENTER the university. Ordinarily, students apply for admission to the Actuarial Science major in the fall semester of their sophomore year, after they have taken Math:2850 (22M:028) Calculus III or MATH:3770 (22M:055) Fundamental Properties of Spaces and Functions I and STAT:3100 (22S:130) Introduction to Mathematical Statistics I.
    [Show full text]
  • UMBC Alumnae Racing to Develop Coronavirus Vaccine
    Newsletter SPRING 2020 To our UMBC/Meyerhoff families: We hope you and your families are all doing well during this strange and stressful time of Covid- 19. Although the world has changed quickly with so many things shut down and many of us sheltering at home, we hope this newsletter will represent a ray of sunshine during a dark and difficult time. Please enjoy this positive representation of our student and alumni community. MPA Board UMBC Alumnae Racing to Develop Coronavirus Vaccine Kizzmekia Corbett ’08, M16, biological sciences, says it feels like she’s “living in a constant adrenaline rush.” Maybe that’s because she and her team at the Vaccine Research Center at the National Insti- tute of Allergy and Infectious Diseases have been working around the clock for weeks. They’re racing to develop a vaccine for the coronavirus faster than it can race across the globe. “To be living in this moment where I have the opportunity to work on something that has imminent global importance…it’s just a surre- al moment for me,” Corbett says. Despite it feeling surreal, the advances Corbett and her team are making are very real, and they’re setting records. “We are making better progress than I could have ever hoped for,” she says. After three months of studies in test tubes and in animals, the vaccine her team developed is about to enter a phase I clinical trial, a crucial hur- dle on the way to FDA approval. Read the complete article about Kizzmekia and her team’s efforts to develop a Covid-19 vaccine in the latest UMBC magazine at https:// Kizzmekia Corbett, NIH magazine.umbc.edu/umbc-alumnae-racing-to-develop- coronavirus-vaccine/.
    [Show full text]
  • The Solidarity Trial ‘Solidarity’ Is an International Clinical Trial to Help Find an Effective Treatment for COVID-19, Launched by the WHO and Partners
    CORONAVIRUS (COVID-19) UPDATE NO. 22 / LAST UPDATED: 16 APRIL 2020 CURRENT SITUATION | COVID-19 RESPONSE | SCIENCE | FAITH COMMUNITY | RESOURCES CORONAVIRUS UPDATE 22 The Solidarity Trial ‘Solidarity’ is an international clinical trial to help find an effective treatment for COVID-19, launched by the WHO and partners. Find out which therapies are included in the trial. MORE Transmission Measures to reduce Guidance for the faith scenarios transmission community EPI WiN CORONAVIRUS (COVID-19) UPDATE NO. 22 / LAST UPDATED: 16 APRIL 2020 CURRENT SITUATION | COVID-19 RESPONSE | SCIENCE | FAITH COMMUNITY | RESOURCES Current global situation • Nearly 2 million confirmed cases • More than 123 000 deaths USA has more than 575 000 confirmed cases – • the most in the world Top ten countries with the highest number of new cases COUNTRY NEW REPORTED CASES IN LAST 24HRS United States of America 24 446 For the latest data, please access: France 5 483 è WHO situation dashboard United Kingdom 5 252 è WHO situation reports Turkey 4 062 è UNWFP world travel restrictions Russian Federation 3 388 Spain 3 045 Italy 2 972 Germany 2 486 Islamic Republic of Iran 1 574 Canada 1 360 Data as of 15.04.20 EPI WiN CORONAVIRUS (COVID-19) UPDATE NO. 22 / LAST UPDATED: 16 APRIL 2020 CURRENT SITUATION | COVID-19 RESPONSE | SCIENCE | FAITH COMMUNITY | RESOURCES Number of new cases of COVID-19 per day, by WHO Region 100 000 90 000 80 000 70 000 60 000 50 000 New daily cases New 40 000 30 000 20 000 10 000 0 * 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 March April AFRO AMRO EMRO EURO SEARO WPRO * There is no data from 22 March due to a change in the WHO situation reporting period EPI WiN CORONAVIRUS (COVID-19) UPDATE NO.
    [Show full text]
  • Actuarial Studies Within the Biometry and Statistics and Statistical Science Majors
    Actuarial Studies within the Biometry and Statistics and Statistical Science majors An actuary is a business professional who analyzes the financial consequences of risk. Actuaries use mathematics, statistics and financial theory to study uncertain future events, especially those of concern to insurance and pension programs. They evaluate the likelihood of those events, design creative ways to reduce the likelihood and decrease the impact of adverse events that actually do occur. To be more specific, actuaries improve financial decision making by developing models to evaluate the current financial implications of uncertain future events. Actuaries are an important part of the management team of the companies that employ them. Their work requires a combination of strong analytical skills, business knowledge and understanding of human behavior to design and manage programs that control risk. No matter the source, actuary is consistently rated as one of the best jobs in America. US News and World Report, the Jobs Rated Almanac, CNN Money, and others all agree: few other occupations offer the combination of benefits that an actuarial career can offer. In almost every job satisfaction category, such as work environment, employment outlook, job security, growth opportunity, and salary (especially starting salary), a career as an actuary is hard to beat. Required courses for the Biometry and Statistics and Statistical Science majors Calculus I and II: MATH 1110 & 1120 Multivariable Calculus and Linear Algebra: MATH 2210 & 2220 or 2230 & 2240
    [Show full text]
  • Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks
    Perspective Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks Ralf Wagner, Eberhard Hildt , Elena Grabski, Yuansheng Sun, Heidi Meyer, Annette Lommel, Brigitte Keller-Stanislawski, Jan Müller-Berghaus and Klaus Cichutek * Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany; [email protected] (R.W.); [email protected] (E.H.); [email protected] (E.G.); [email protected] (Y.S.); [email protected] (H.M.); [email protected] (A.L.); [email protected] (B.K.-S.); [email protected] (J.M.-B.) * Correspondence: [email protected] Abstract: Multiple preventive COVID-19 vaccines have been developed during the ongoing SARS coronavirus (CoV) 2 pandemic, utilizing a variety of technology platforms, which have different properties, advantages, and disadvantages. The acceleration in vaccine development required to combat the current pandemic is not at the expense of the necessary regulatory requirements, including robust and comprehensive data collection along with clinical product safety and efficacy evaluation. Due to the previous development of vaccine candidates against the related highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the antigen that elicits immune protection is known: the surface spike protein of SARS-CoV-2 or specific domains encoded in that protein, e.g., the receptor binding domain. From a scientific point of view and in accordance with legal Citation: Wagner, R.; Hildt, E.; frameworks and regulatory practices, for the approval of a clinic trial, the Paul-Ehrlich-Institut Grabski, E.; Sun, Y.; Meyer, H.; requires preclinical testing of vaccine candidates, including general pharmacology and toxicology as Lommel, A.; Keller-Stanislawski, B.; well as immunogenicity.
    [Show full text]
  • WHO COVID-19 Database Search Strategy (Updated 26 May 2021)
    Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR
    [Show full text]
  • An Examination of COVID-19 Medications' Effectiveness
    healthcare Review An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review Mahmoud Al-Masaeed 1,* , Mohammad Alghawanmeh 2, Ashraf Al-Singlawi 3 , Rawan Alsababha 4 and Muhammad Alqudah 1 1 Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia; [email protected] 2 Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan; [email protected] 3 Independent Scholar, Amman 11731, Jordan; [email protected] 4 School of nursing and Midwifery, Western Sydney University, Sydney 2560, Australia; [email protected] * Correspondence: [email protected] Abstract: Background: The review seeks to shed light on the administered and recommended COVID- 19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO Citation: Al-Masaeed, M.; solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings Alghawanmeh, M.; Al-Singlawi, A.; indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been Alsababha, R.; Alqudah, M. An useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the Examination of COVID-19 need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, Medications’ Effectiveness in minerals, and supplements has been linked to increased immunity and thus offering the body a Managing and Treating COVID-19 fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and Patients: A Comparative Review.
    [Show full text]
  • Solidarity” Clinical Trial for COVID-19
    WHO’s “Solidarity” Clinical Trial for COVID-19 • Given the extreme pressure that COVID-19 is placing on health care systems worldwide, there is a pressing need to expeditiously identify therapies that can slow the progression of the disease in patients and/or increase the chances of survival. While randomized clinical trials normally take years to design and conduct, the world is currently in the midst of a fast-moving pandemic, and time is not on our side. • As a result, on March 20th, the World Health Organization (WHO) announced “Solidarity,” an international clinical trial that seeks to rapidly identify effective treatments for COVID-19. Currently, 1200 patients have already been randomized from five countries, with 600 hospitals ready to begin enrolling patients this week. • The trial seeks to compare the safety and efficacy of four different medications: Remdesivir, an experimental drug that has shown some promise in animal tests on two other coronaviruses—MERS and SARS; Lopinavir/Ritonavir, a drug combination used to treat HIV; Interferon beta-1a, used to treat multiple sclerosis; and chloroquine and hydroxychloroquine, drugs that are used to treat malaria and rheumatological conditions, respectively. As data becomes available, the list of drugs being tested could be modified, with the addition of new therapies or deletion of older ones. • The trial is designed to be as simple as possible so that it can be replicated even in hospitals that have been overwhelmed by an onslaught of cases. When a patient is deemed eligible to participate and consents, a physician will enter the patient’s data, including underlying conditions that could affect the course of treatment, into a WHO website which will then randomly assign a treatment option, consisting of either the local standard of care or the local of standard of care plus one of the above-mentioned treatments.
    [Show full text]
  • Infodemic: How Has the Epidemic of Misinformation Affected the Response to COVID-19?
    20 Infodemic: How Has the Epidemic of Misinformation Affected the Response to COVID-19? Series | COVID-19 & response strategy Authors: Carlos Chaccour (ISGlobal), Rafael Vilasanjuan (ISGlobal)* [ This is the twentieth Misinformation has played an impor- ment of the president of the United document in a series tant role during the COVID-19 pandem- States—as well as the inclusion of iver- of discussion notes ic. A general public desperate for reliable mectin in the national therapeutic guide- addressing fundamental data and a scientific publishing industry lines of Peru and Bolivia on the basis of questions about still characterised by many features of the in vitro experiments and fraudulent data2. COVID-19 and response Gutenberg era have contributed to a par- Other critical areas where false or mis- strategies. These allel pandemic: an infodemic. The term represented information has played a role documents are based infodemic refers to an overabundance of during this pandemic include the debate on the best scientific information—some accurate, some not— around the protection of children dur- information available on a particular subject. The World Health ing confinement, theuse of face masks and may be updated as Organisation (WHO) has long used this and the actual level and duration of im- new information comes term to describe an excess of information to light.] munity to the virus. This epidemic of about a topic, including many hoaxes or misinformation has been exacerbated by rumours, which make it difficult to find rushed scientific publication, the prioriti- reliable sources and guidance. sation of partisan activism over evidence, Most aspects of the COVID-19 debate and a general excess of opinions and de- have been burdened by this infodemic.
    [Show full text]
  • COVID-19Predict – Predicting Pandemic Trends
    medRxiv preprint doi: https://doi.org/10.1101/2020.09.09.20191593; this version posted September 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: COVID-19Predict – Predicting Pandemic Trends. Authors Jürgen Bosch1,2, Austin Wilson3, Karthik O’Neil4, Peter A. Zimmerman5,6 Institutional Affiliations 1 Division of Pediatric Pulmonology and Allergy/Immunology, Case Western Reserve University, Cleveland, OH, United States 2InterRayBio, LLC, Baltimore, MD, United States 3 Department of Computer Science, Case Western Reserve University, Cleveland, OH, United States 4 Andrews Osborne Academy (AOA), Willoughby, OH, United States 5 The Center for Global Health and Diseases, Pathology Department, Case Western Reserve University, Cleveland, OH, United States 6 Masters of Public Health Program, Department of Population Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, United States 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.09.09.20191593; this version posted September 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Abstract Background Given the global public health importance of the COVID-19 pandemic, data comparisons that predict on-going infection and mortality trends across national, state and county-level administrative jurisdictions are vitally important.
    [Show full text]
  • March 11, 2021
    Sector Email 3.11.2021 Subject header: Updates on COVID-19 from Public Health - Seattle & King County (PHSKC) Schools Dear school partners, March is Women’s History Month and this year we are grateful to some of the women who are making history by changing the course of the COVID-19 pandemic. Have you learned about Kizzmekia Corbett, an African American Immunologist who co-led the development of the Moderna COVID-19 vaccine. This month, we celebrate Dr. Corbett and thousands of her colleagues in healthcare, research and public health as women who are making history. Reminder: please review the King County Schools COVID-19 Response Toolkit, related resources, and training videos. ---------- This week’s Public Health—Seattle & King County (PHSKC) Schools and Child Care Task Force sector email includes the following topics: 1. Key indicators of COVID-19 activity 2. Vaccine Updates a. Educators, school staff and child care workers now eligible for COVID-19 vaccine b. How school and child care staff can access vaccines c. Getting Vaccinated Resources d. Signs and Symptoms Following Vaccination 3. COVID Community Vaccination Event Planning Workbooks 4. Special Enrollment for Washington Health Care 5. Updated Mask Posters 6. Events a. Public Health’s upcoming trainings and community discussions on COVID-19 b. COVID-19 Vaccination Webinar and Q&A c. COVID-19 Vaccine Distribution Webinar and Q&A d. Oromo Session – COVID-19 and Vaccinations e. Somali Session – COVID-19 and Vaccinations 7. Updated Guidance from the CDC – When You’ve Been Fully Vaccinated 8. School and District Town Hall Meetings 9.
    [Show full text]